Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125405751 | 12540575 | 1 | I | 20160331 | 20160624 | 20160708 | 20160708 | EXP | IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-119909 | RANBAXY | 36.68 | YR | F | Y | 0.00000 | 20160708 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125405751 | 12540575 | 1 | PS | OXALIPLATIN. | OXALIPLATIN | 1 | Intravenous (not otherwise specified) | 150 MG CYCLICAL | U | U | 202922 | 150 | MG | ||||||
| 125405751 | 12540575 | 2 | SS | CAPECITABINE. | CAPECITABINE | 1 | Oral | 3000 MG CYCLICAL | U | U | 0 | 3000 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125405751 | 12540575 | 1 | Adenocarcinoma of colon |
| 125405751 | 12540575 | 2 | Adenocarcinoma of colon |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125405751 | 12540575 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125405751 | 12540575 | Thrombocytopenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125405751 | 12540575 | 1 | 20160303 | 20160324 | 0 | |
| 125405751 | 12540575 | 2 | 20160303 | 20160324 | 0 |